[$$] Allergan Pursuer Valeant: A Drug Maker With Little Patience for Science

[at The Wall Street Journal] – Allergan spends 17% of its revenue on R&D. Michael Pearson has cut Valeant’s spending to 3%, setting up a culture clash as he attempts to purchase the Botox maker. more

View todays social media effects on AGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Allergan is hiring next, click here to view